Atlas Trials

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

Clinical trial NCT02684617 · TERMINATED

Trial details

NCT number
NCT02684617
Sponsor
Merck Sharp & Dohme LLC
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
rrCLLrrMMrrDLBCL
Start date
2016-03-29
Primary completion
2020-04-06
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.